Morocco Has Factories but Lacks WHO Level 3 Rating Ethiopia Holds

Morocco has built one of Africa’s most established pharmaceutical industries, yet it still lacks the World Health Organization’s Level 3 regulatory maturity rating that Ethiopia already holds — a gap that the industry identifies as the main reason Rabat is facing challenges in the race to become the continent’s medicine hub.

The comparison surfaced at the African Health Products Manufacturing Exhibition and Conference in Addis Ababa in late October, where Ethiopia’s Health Deputy Minister Muluken Argaw presented his country as a future continental manufacturing center, anchored in the African Continental Free Trade Area (AfCFTA).

He put the Ethiopian pharmaceutical market at more than $4 billion by 2030. Here is why that matters: the AfCFTA covers more than a billion people, and Africa currently produces barely 3% of the medicines it consumes, importing between 70% and 90% of them.

Morocco, by contrast, has the factories. Karim El Fellah, expert in pharmaceutical industry, describes a sector with roughly fifty production units, more than 21 billion dirhams in annual revenue — about 1.5% of GDP — and over sixty years of accumulated know-how, particularly in generics since the 1990s.

Local production covers “between 60% and 80% of national needs in volume depending on the year and the source,” he says; the Health Minister put the figure at around 70% for 2024.

But there is a catch. In value terms, the picture darkens: innovative drugs, biologics and biosimilars — the expensive products — remain largely imported, so the local share of spending is probably much lower than the volume share suggests. And only about 10% of Moroccan production is exported.

A rating Ethiopia already has

The first bottleneck is regulatory. Ethiopia’s medicines authority has been assessed by the WHO at maturity level 3, joining Egypt, South Africa, Nigeria, Ghana, Rwanda and Senegal. “Morocco has not yet reached WHO maturity level 3,” El Fellah points out, despite a WHO field mission in December 2025 and the adoption of the reform of the medicines code. The evaluation continues.

The commercial consequences are direct. “Without WHO Level 3 maturity, a Moroccan medicine must go through country-by-country evaluations, especially in Africa, and institutional buyers look at it with more reserve and mistrust,” he says. In practice, everything hinges on mutual recognition between continental regulators — and that recognition is tied to the WHO maturity rating.

How the lead was lost

An actor of the pharmaceutical industry having requested anonymity said that Morocco long held the reins of African pharmaceutical industry before ceding this position to other countries, following “several complications.” The source lists four.

First, dysfunctions of the Directorate of Drug and Pharmacy, today replaced by the AMMPS, in granting authorizations. Second, support “almost absent” from the State to production laboratories. Third, support for research and development. Fourth, the “rarity of pharmacist-researcher profiles.”

The consequence, according to the source, is industrial: “The majority of pharmaceutical laboratories turned to the production of low-cost generics and to importation.”

Then there is the skills problem. Regulatory affairs, quality, pharmacovigilance — “these are precisely the profiles needed to pass this evaluation, and they take several years to train,” El Fellah says. Having worked at the medicines agency and in industry, he observes that “these profiles are missing on both sides.”

For the agency to succeed, it must focus on “its core mission: evaluating, authorizing, inspecting and monitoring drug safety,” which requires giving it “the human resources and the autonomy to do so.”

Two ambitions, side by side

El Fellah judges Ethiopia’s ambition credible “on paper and on the generics front,” while vaccines, insulin, oncology drugs and African-sourced active ingredients are, on a ten-year horizon, “more uncertain for lack of skills.” Morocco’s own industrial gaps weigh in the other direction: biosimilars and biotechnology, minimal production of active pharmaceutical ingredients, and heavy dependence on imported raw materials.

Indicator Morocco Ethiopia
WHO maturity level 3 Not yet reached; evaluation ongoing Achieved; regulator WHO-recognized
Market size More than 21 billion dirhams in revenue More than $4 billion expected by 2030
Industrial base About fifty production units Dedicated industrial park
Local coverage of national needs 60–80% by volume Not stated

The competitive field does not stop at Addis Ababa. “Egypt and South Africa rank as the two main pharmaceutical powers on the continent, and Morocco is part of the leading pack,” El Fellah says. Algeria and Tunisia stand out in generics through import-substitution models, while Ethiopia, Nigeria and Kenya are the new entrants — Nigeria with a local-manufacturing policy, Kenya with a state strategy.

What would move fastest

Which single decision would lift Moroccan competitiveness quickest? Finishing the WHO level 3 evaluation and making it the calendar’s priority, El Fellah argues: “It is the decision that opens the possibility of exporting under the AfCFTA.” Next come shorter marketing-authorization timelines and giving priority to Moroccan-made generics in public tenders, a demand he says manufacturers and recent pro-local-manufacturing initiatives have pressed.

The regulator is already moving. Samir Ahid, director general of the AMMPS, announced at a Competition Council conference in Marrakech on October 14 that generic penetration “has reached 60% in volume” — calling the industry a “national pride” — and unveiled a draft decree introducing conditional and accelerated marketing authorizations, on the grounds that “market access timelines must be reduced.”

Hamza Guedira, president of the National Order of Pharmacists, frames the stakes in one condition: “we only export a model if it is solid at home.”

Morocco, a North African kingdom of roughly 37 million people, has coastlines on both the Mediterranean and the Atlantic, with Rabat as its capital and Casablanca its largest city. The Moroccan state traces its origins to the Idrisid dynasty founded in 788, and the Alawi dynasty, in power since 1631, is among the world’s oldest reigning royal dynasties.

Unlike much of the continent, Morocco escaped Ottoman dominion, was placed under French and Spanish protectorates in 1912, and regained independence in 1956 under Sultan Muhammad V. Today it has the fifth-largest economy in Africa, and the country is considered Africa’s leading industrial economy — a base that underpins the pharmaceutical sector’s continental ambitions.

For international investors and supply-chain planners, the dividing line is stark: Morocco has the industrial fabric; Ethiopia already has the WHO’s level 3 stamp. What to watch next is the outcome of Morocco’s WHO evaluation, still in progress according to El Fellah — the decision that, in his words, opens the door to exporting under the AfCFTA.

Photo of author

World Desk

World Desk at Archyde.

GTA VI Sales Top $2.36 Billion in 24 Hours, Sensor Tower Finds

Days of Our Lives’ Actor Larry Poindexter Dies at 66 After Being Struck by Vehicle